FY2025 EPS Estimates for Codexis Lifted by Cantor Fitzgerald

Codexis, Inc. (NASDAQ:CDXS - Free Report) - Equities researchers at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for Codexis in a note issued to investors on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnology company will earn ($0.49) per share for the year, up from their prior estimate of ($0.51). Cantor Fitzgerald has a "Overweight" rating and a $11.00 price target on the stock. The consensus estimate for Codexis' current full-year earnings is ($0.77) per share.

Codexis Price Performance

Shares of NASDAQ:CDXS traded down $0.19 on Thursday, reaching $2.63. 1,474,205 shares of the company were exchanged, compared to its average volume of 583,631. The firm has a market cap of $217.86 million, a price-to-earnings ratio of -3.02 and a beta of 2.12. Codexis has a 1-year low of $2.47 and a 1-year high of $6.08. The company has a 50-day moving average of $4.29 and a 200-day moving average of $3.96. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39.

Codexis (NASDAQ:CDXS - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.09). Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. The firm had revenue of $21.46 million during the quarter, compared to analyst estimates of $27.41 million.

Remove Ads

Institutional Trading of Codexis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Summit Investment Advisors Inc. lifted its stake in shares of Codexis by 81.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,428 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 3,783 shares in the last quarter. Wolverine Trading LLC bought a new position in shares of Codexis in the fourth quarter worth $56,000. Fiduciary Trust Co acquired a new stake in shares of Codexis in the fourth quarter valued at $65,000. Intech Investment Management LLC bought a new stake in shares of Codexis during the 3rd quarter worth $66,000. Finally, Group One Trading LLC acquired a new stake in Codexis during the 4th quarter valued at $73,000. Hedge funds and other institutional investors own 78.54% of the company's stock.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.